NSCLC patients exhibit reduced quantities of peripheral NK cells, characterized by a unique receptor expression pattern featuring decreased levels of NKp30, NKp80, CD16, DNAM1, KIR2DL1, and KIR2DL2, while NKp44, NKG2A, CD69, and HLA‐DR are upregulated. The gene discussed is CD69; the disease is non-small cell lung carcinoma.